Denisa Kacerovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Denisa Kacerovska has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Karel Pizinger
Department of Dermatovenereology, Charles University, Faculty of Medicine, University Hospital, Pilsen, Czech Republic
2 shared publications - Filip Majer
Charles University, 1st Faculty of Medicine
1 shared publication František Šmíd
Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
1 shared publicationMagda Kumpova
From the Department of Dermatology and Venerology, Medical Faculty, Charles University, Dr. E. Beneše 13, 305 99 Pilsen, Czech Republic
1 shared publication- Petra Cetkovska
Department of Dermatovenereology, Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic
1 shared publication
Latest Publications
- 7 January 2008
- Published by Wiley in Photochemistry and Photobiology
- Vol. 84 (3) , 779-785
Photodynamic Therapy of Nonmelanoma Skin Cancer with Topical Hypericum perforatum Extract—A Pilot Study
Hypericin, the photoactive compound of Hypericum perforatum, is probably the most powerful photosensitizer found in nature. This compound has shown high potency in the photodynamic treatment of tumor cells. However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells. The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ). The study was carried out on 34 patients—eight with actinic keratoses (AKs), 21 with BCC and five with Bowen’s disease. The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm−2 of red light 2 h later. The treatment was performed weekly for 6 weeks on average. The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen’s disease. There was only a partial remission seen in patients with nodular BCCs. A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen’s disease. All patients complained of burning and pain sensations during irradiation. Although the results of this first clinical trial could be regarded as disappointing, there are still possibilities for improvement. Better preparation of the lesions, enhancement of hypericin delivery and other types of light exposure procedures could significantly improve the clinical outcomes of this relatively inexpensive treatment modality.
- 7 January 2008
- Published by Wiley in Photochemistry and Photobiology
- Vol. 84 (3) , 779-785
Photodynamic Therapy of Nonmelanoma Skin Cancer with Topical Hypericum perforatum Extract—A Pilot Study
Hypericin, the photoactive compound of Hypericum perforatum, is probably the most powerful photosensitizer found in nature. This compound has shown high potency in the photodynamic treatment of tumor cells. However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells. The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ). The study was carried out on 34 patients—eight with actinic keratoses (AKs), 21 with BCC and five with Bowen’s disease. The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm−2 of red light 2 h later. The treatment was performed weekly for 6 weeks on average. The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen’s disease. There was only a partial remission seen in patients with nodular BCCs. A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen’s disease. All patients complained of burning and pain sensations during irradiation. Although the results of this first clinical trial could be regarded as disappointing, there are still possibilities for improvement. Better preparation of the lesions, enhancement of hypericin delivery and other types of light exposure procedures could significantly improve the clinical outcomes of this relatively inexpensive treatment modality.
- 20 November 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (6) , 295-297
Genital Warts Treated By Photodynamic Therapy
The patient, a 30‐year‐old man with numerous genital condylomata acuminata (CA), has had unsuccessful treatment with liquid nitrogen, 20% podophyllin, and repeated 0.5% podophyllotoxin solution with 5% imiquimod (Figure 1). Before the appearance of CA, he experienced acute orchiepididimitis and a Candida infection. The patient was immunologically examined, and the lower level of lymphocytes, slightly reduced level of IgM, and C4 complement were revealed. Results from a human immunodeficiency virus examination were negative. After the therapeutic failure mentioned above, photodynamic therapy (PDT) was initiated using 20% aminolevulinic acid (5‐ALA) in a gel. The photosensitizer was applied to lesions and 10 mm of surrounding skin in a 1‐mm‐thick layer under occlusive dressing for 3 hours and then removed with saline and nonwoven gauze. The site was immediately irradiated with noncoherent red light with an emission spectrum of 580 to 680 nm wavelength (Medeikonos PDT‐Model 200, Medeikonos AB, Sweden). The total light dose was 50 J/cm2; light intensity ranged from 70 to 90 mW/cm2. Because of persistent fluorescence during photodynamic therapy, the treatment was repeated 10 times in 2‐week intervals with a follow‐up of 1, 3, and 6 months after its completion. After the last PDT treatment, the persistent fluorescence disappeared completely. The absence of fluorescence corresponded with a healed clinical finding without scarring and pigmentation (Figure 2). The period from the initiation of PDT to the consolidation of CA was 22 weeks. During PDT treatment, the patient felt only mild burning, which disappeared after the illumination stopped. Six months after the therapy, there were no signs of recurrent disease. Condylomata acuminata before photodynamic therapy. image Clinical finding 6 months following photodynamic therapy. image
- 20 November 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (6) , 295-297
Genital Warts Treated By Photodynamic Therapy
The patient, a 30‐year‐old man with numerous genital condylomata acuminata (CA), has had unsuccessful treatment with liquid nitrogen, 20% podophyllin, and repeated 0.5% podophyllotoxin solution with 5% imiquimod (Figure 1). Before the appearance of CA, he experienced acute orchiepididimitis and a Candida infection. The patient was immunologically examined, and the lower level of lymphocytes, slightly reduced level of IgM, and C4 complement were revealed. Results from a human immunodeficiency virus examination were negative. After the therapeutic failure mentioned above, photodynamic therapy (PDT) was initiated using 20% aminolevulinic acid (5‐ALA) in a gel. The photosensitizer was applied to lesions and 10 mm of surrounding skin in a 1‐mm‐thick layer under occlusive dressing for 3 hours and then removed with saline and nonwoven gauze. The site was immediately irradiated with noncoherent red light with an emission spectrum of 580 to 680 nm wavelength (Medeikonos PDT‐Model 200, Medeikonos AB, Sweden). The total light dose was 50 J/cm2; light intensity ranged from 70 to 90 mW/cm2. Because of persistent fluorescence during photodynamic therapy, the treatment was repeated 10 times in 2‐week intervals with a follow‐up of 1, 3, and 6 months after its completion. After the last PDT treatment, the persistent fluorescence disappeared completely. The absence of fluorescence corresponded with a healed clinical finding without scarring and pigmentation (Figure 2). The period from the initiation of PDT to the consolidation of CA was 22 weeks. During PDT treatment, the patient felt only mild burning, which disappeared after the illumination stopped. Six months after the therapy, there were no signs of recurrent disease. Condylomata acuminata before photodynamic therapy. image Clinical finding 6 months following photodynamic therapy. image